GlobalData on MSN1d
FDA expands Pfizer’s RSV vaccine label to include all high-risk adultsAbrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
GlobalData on MSN10h
US CDC AdCom recommends lowering the age for pneumococcal vaccinesThe committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
MedPage Today on MSN1d
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk AdultsThe FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
In a 15-0 vote, ACIP recommended that MenB-4C be administered as a two-dose series at 0 and 6 months when given to healthy ...
BioNTech (NASDAQ: BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...
Sangamo Therapeutics, Inc. , a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear regulatory pathway to Accelerated Approval ...
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback